These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 8287635)

  • 1. Multiple-dose pharmacokinetics of pefloxacin in patients with hepatocellular deficiency.
    Galtier M; Bressolle F; de la Coussaye JE; Gomeni R; Joubert P; Gény F; Dubois A; Raffanel C; Saissi G; Eledjam JJ
    Clin Pharmacokinet; 1993 Nov; 25(5):415-23. PubMed ID: 8287635
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and tissue distribution of intravenous pefloxacin for antibiotic prophylaxis in biliary surgery.
    Gascón AR; Campo E; Olea E; Hernández RM; Calvo B; Errasti J; Pedraz JL
    Biopharm Drug Dispos; 2002 Oct; 23(7):293-300. PubMed ID: 12355580
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of Bayesian estimation to discriminate subpopulations of patients with altered pharmacokinetics using fragmentary data: a pilot study with pefloxacin.
    Bruno R; Rosier P; Iliadis A; Le Roux Y; Montay G; Frydman A; Gaillot J
    Eur J Drug Metab Pharmacokinet; 1991; Spec No 3():338-45. PubMed ID: 1820906
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative oral pharmacokinetics of fleroxacin and pefloxacin.
    De Lepeleire I; Van Hecken A; Verbesselt R; Tjandra-Maga TB; De Schepper PJ
    J Antimicrob Chemother; 1988 Aug; 22(2):197-202. PubMed ID: 3141343
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pefloxacin clinical pharmacokinetics.
    Bressolle F; Gonçalves F; Gouby A; Galtier M
    Clin Pharmacokinet; 1994 Dec; 27(6):418-46. PubMed ID: 7882634
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of pefloxacin and amikacin administered simultaneously to intensive care patients.
    Sultan E; Richard C; Pezzano M; Auzepy P; Singlas E
    Eur J Clin Pharmacol; 1988; 34(6):637-43. PubMed ID: 3169115
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Report: pharmacokinetic and drug interaction studies of pefloxacin with paracetamol (NNAID) in healthy volunteers in Pakistan.
    Gauhar S; Ali SA; Naqvi SB; Shoaib MH
    Pak J Pharm Sci; 2014 Mar; 27(2):389-95. PubMed ID: 24577931
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinico-pharmacologic studies on pefloxacin].
    Ludwig E; Székely E; Csiba A
    Orv Hetil; 1994 Mar; 135(13):687-92. PubMed ID: 8170669
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Concentration-time courses of pefloxacin in plasma and milk of lactating she-camels (Camelus dromedarius).
    Goudah A; Shah SS; Shin HC; Chang BJ; Shim JH; Abd El-Aty AM
    Berl Munch Tierarztl Wochenschr; 2008; 121(11-12):432-9. PubMed ID: 19086693
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Penetration of pefloxacin into gynaecological tissues.
    Bouvet O; Bressolle F; Courtieu C; Galtier M
    J Antimicrob Chemother; 1992 May; 29(5):579-87. PubMed ID: 1624396
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disposition kinetics and urinary excretion of pefloxacin after intravenous injection in crossbred calves.
    Srivastava AK; Dumka VK; Deol SS
    Vet Res Commun; 2000 Apr; 24(3):189-96. PubMed ID: 10836277
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics and tissue residues of pefloxacin and its metabolite norfloxacin in broiler chickens.
    Pant S; Rao GS; Sastry KV; Tripathi HC; Jagmohan ; Malik JK
    Br Poult Sci; 2005 Oct; 46(5):615-20. PubMed ID: 16359117
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Diffusion of pefloxacin in the aqueous humor and crystalline lens after repeated oral administration in man].
    Salvanet-Bouccara A; Montay G; Fisch A; Forestier F; Meziane D; Lafaix C; Prieur MB
    J Fr Ophtalmol; 1991; 14(4):260-4. PubMed ID: 1955654
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of rifampin on the pharmacokinetics of pefloxacin.
    Humbert G; Brumpt I; Montay G; Le Liboux A; Frydman A; Borsa-Lebas F; Moore N
    Clin Pharmacol Ther; 1991 Dec; 50(6):682-7. PubMed ID: 1752112
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of omeprazole given by continuous intravenous infusion to patients with varying degrees of hepatic dysfunction.
    Piqué JM; Feu F; de Prada G; Röhss K; Hasselgren G
    Clin Pharmacokinet; 2002; 41(12):999-1004. PubMed ID: 12222996
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral pharmacokinetics and ascitic fluid penetration of pefloxacin in cirrhosis.
    Cardey J; Silvain C; Bouquet S; Breux JP; Becq-Giraudon B; Fourtillan JP; Beauchant M
    Eur J Clin Pharmacol; 1987; 33(5):469-72. PubMed ID: 3480805
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of ketoprofen (NSAID) on the pharmacokinetics of pefloxacin and ofloxacin in healthy volunteers.
    Fillastre JP; Leroy A; Borsa-Lebas F; Etienne I; Gy C; Humbert G
    Drugs Exp Clin Res; 1992; 18(11-12):487-92. PubMed ID: 1308475
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics and imaging properties of Gd-EOB-DTPA in patients with hepatic and renal impairment.
    Gschwend S; Ebert W; Schultze-Mosgau M; Breuer J
    Invest Radiol; 2011 Sep; 46(9):556-66. PubMed ID: 21623212
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pefloxacin kinetics in cirrhosis.
    Danan G; Montay G; Cunci R; Erlinger S
    Clin Pharmacol Ther; 1985 Oct; 38(4):439-42. PubMed ID: 3862496
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of pharmacokinetics and safety of ponatinib in subjects with chronic hepatic impairment and matched healthy subjects.
    Narasimhan NI; Dorer DJ; Davis J; Turner CD; Marbury TC; Sonnichsen D
    Cancer Chemother Pharmacol; 2014 Aug; 74(2):341-8. PubMed ID: 24934866
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.